India  
 
NewsR.in

Favipiravir

Experimental antiviral drug with potential activity against RNA viruses

Favipiravir    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Favipiravir: Experimental antiviral drug with potential activity against RNA viruses
Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.

0
shares		ShareTweetSavePostSend
 

You Might Like


COVID-19 medicine: Lupin launches Favipiravir in India at Rs 49 per tablet

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use on COVID-19 patients as a potential treatment
DNA - Published

Cipla to launch COVID-19 treatment drug Favipiravir: CSIR

The death toll has gone up to 30,601 with 740 fatalities reported in the last 24 hours.
DNA - Published

Anti-viral drug Favipiravir shows clinical improvement in mild, moderate COVID-19 cases: Glenmark

Glenmark announced the launch of the first oral Favipiravir claiming that it is backed by strong clinical evidence showing encouraging results in patients with mild to moderate COVID-19.
DNA - Published

Fujifilm says COVID-19 drug research may drag on into July

Fujifilm Holdings Corp's research on Avigan as a potential treatment for COVID-19 may drag on until July, the company said on Sunday, a further setback in the Japanese firm's race to find a vaccine.
Reuters India - Published

Russia backing antiviral drug Avifavir for Covid-19 fight good news for India, say scientists

Russia's approval of the antiviral drug Avifavir to treat Covid-19 is good news for India as it is based on an influenza medication already in advanced clinical trials here, say scientists.Avifavir,..
IndiaTimes - Published

Mumbai firm may become first in India to develop anti-retroviral drug for Covid-19

In an indication of innovation in pharmaceuticals for Covid, Mumbai-based Glenmark may become the first company in India to offer an anti-retroviral, Favipiravir, from a class of drugs which has shown..
IndiaTimes - Published

Covid-19: Mumbai firm seeks regulator nod for ARV trials

In an indication of innovation in pharmaceuticals for Covid-19, Mumbai-based Glenmark may become the first company in India to offer an anti-retroviral, a class of drugs which has shown promise, and is..
IndiaTimes - Published